MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies

Setijono, Stephanie Rebecca; Kwon, Hyog Young; Song, Su Jung

doi:10.3389/fonc.2017.00331

Cited by 4 publications

(2 citation statements)

References 110 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRs) are a classical non-coding small RNA playing crucial regulatory roles in diverse pathological and physiological progresses by a posttranscriptional mechanism through binding the 3 ′ -untranslated regions (3 ′ -UTR) of target genes (9)(10)(11)(12). And miRs can act as tumor oncogenes or suppressors through regulating their target genes that are usually dysregulated in cancer (13)(14)(15). In our current study, we have proven that miR-936 expression profile is meaningfully reduced in LSCC specimens, and overexpression of miR-936 suppresses LSCC cells proliferation migration and invasion.…”

Section: Introductionmentioning

confidence: 99%

miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78

Lin

Liu

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

MicroRNAs (miRs) play important roles in tumor progression. miR-936 has been reported to suppress cell invasion and proliferation of glioma and non-small cell lung cancer. Nevertheless, the function of miR-936 in laryngeal squamous cell carcinoma (LSCC) remains undiscovered. Hence, our study was to investigate the role of miR-936 in LSCC.In our present research, we have testified that miR-936 was substantially downregulated in LSCC tissues compared with adjacent normal tissues. Furthermore, miR-936 could inhibit proliferation, migration and invasion, and improve the sensitivity to doxorubicin and cisplatin of LSCC cells. Additionally, luciferase reporter assays were performed to confirm that GPR78 was a novel target of miR-936, and the protein expression of GPR78 was obviously inhibited by miR-936 in LSCC cells. In summary, our study indicates that the miR-936/GPR78 axis could be both a diagnostic marker and a therapeutic target for LSCC.

show abstract

Section: Introductionmentioning

confidence: 99%

miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78

Lin

Liu

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition to the cytogenetic aberrations observed in MDS, current studies have also revealed aberrant expression of microRNAs. 104 In MDS with deletion of the long arm of chromosome 5 [del(5q)] alleles of miR143, miR145, and miR146a are deleted within the commonly deleted region located on chromosome 5q32–5q33. 105 Lenalidomide therapy, indicated for this group of patients, leads to normalization of expression of these microRNA.…”

Section: Microrna Expression In Chronic Myelogenous Leukemiamentioning

confidence: 99%

Abnormal microRNA expression in the course of hematological malignancies

Szymczyk¹,

Macheta²,

Podhorecka³

2018

CMAR

View full text Add to dashboard Cite

Research on the carcinogenesis process is currently focused primarily on understanding its genetic basis and molecular abnormalities that may be predictive factors and therapeutic targets. It was clearly confirmed recently that microRNAs are involved in the mechanisms of leukocyte development, differentiation, and apoptosis, as well as in the pathogenesis of proliferative diseases of the hematopoietic system. Currently, research strategies allow determination of the deregulation of microRNA profiles in relation to other cytogenetic aberrations, as well as prognostic factors and primary end points. The problem of the possibility of their use as therapeutic targets is also increasingly discussed. In this article, we analyze literature data on abnormalities in microRNA expression in proliferative diseases of the hematopoietic system in the context of classic cytogenetic and molecular aberrations.

show abstract

microRNA-based Genetic Therapy in Leukemia: Properties, Delivery, and Experimental Models

Zanette

Aoki

Prado

et al. 2023

CGT

View full text Add to dashboard Cite

Leukemia is a type of cancer that affects white blood cells. In this disease, immature blood cells undergo genetic mutations, leading to excessive replication and reduced cell death compared to healthy cells. In cancer, there may be the activation of oncogenes and the deactivation of tumor suppressor genes that control certain cellular functions. Despite the undeniable contribution to the patient's recovery, conventional cancer treatments may have some not-so-beneficial effects. In this case, gene therapy appears as an alternative to classical treatments. Gene therapy delivers genetic material to cells to replace or modify dysfunctional genes, a safe method for neoplasms. One of the types of nucleic acids explored in gene therapy is microRNA (miRNA), a group of endogenous, non-proteincoding, small single-stranded RNA molecules involved in the regulation of gene expression, cell division, differentiation, angiogenesis, migration, apoptosis, and carcinogenesis. This review aims to bring together the most recent advances found in the literature on cancer gene therapy based on microRNAs in the oncological context, focusing on leukemia

show abstract

MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies

Cited by 4 publications

References 110 publications

miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78

miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78

Abnormal microRNA expression in the course of hematological malignancies

microRNA-based Genetic Therapy in Leukemia: Properties, Delivery, and Experimental Models

Contact Info

Product

Resources

About